loading
Overview News Price History Option Chain Discussions Forecast Stock Split
Cogent Biosciences Inc stock is currently priced at $6.65, with a 24-hour trading volume of 467.87K. It has seen a +0.62% increased in the last 24 hours and a -1.18% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.57 pivot point. If it approaches the $6.71 resistance level, significant changes may occur.

Cogent Biosciences Inc Stock (COGT) Financials Data

Cogent Biosciences Inc (COGT) Net Income 2024

COGT net income (TTM) was -$192.41 million for the quarter ending December 31, 2023, a -37.20% decrease year-over-year.
loading

Cogent Biosciences Inc (COGT) Cash Flow 2024

COGT recorded a free cash flow (TTM) of -$156.42 million for the quarter ending December 31, 2023, a -24.64% decrease year-over-year.
loading

Cogent Biosciences Inc (COGT) Earnings per Share 2024

COGT earnings per share (TTM) was -$2.41 for the quarter ending December 31, 2023, a +1.63% growth year-over-year.
loading

Cogent Biosciences Inc Stock (COGT) Latest News

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

pulisher
Benzinga

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

pulisher
GlobeNewswire Inc.

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

pulisher
Benzinga

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

pulisher
GlobeNewswire Inc.

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

pulisher
GlobeNewswire Inc.

Analyst Expectations for Cogent Biosciences's Future

pulisher
Benzinga

About Cogent Biosciences Inc

Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ‘bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

KEY STATS

Previous Close:
$6.61
Market Cap:
$632.00M
24h Volume:
467.87K
1D Range:
$6.55 - $6.92
52W Range:
$3.67 - $13.50
Primary Exchange:

COMPANY PROFILE

NameNameCogent Biosciences Inc
sectorSectorHealthcare (1194)
industryIndustryBiotechnology (685)
webWebunumrx.com
phonePhone617 945 5576
twitter-icon COGT's Discussions on Twitter
clock2024-05-07
location200 Cambridge Park Drive, Suite 3100, Cambridge, United States (02140)

UPGRADES & DOWNGRADES

Initiated Robert W. Baird: Outperform Apr-28-23
Resumed H.C. Wainwright: Buy Mar-27-23
Initiated Needham: Buy Dec-14-22
Initiated Guggenheim: Buy Jun-28-22
Initiated H.C. Wainwright: Buy Oct-11-21
Resumed Jefferies: Buy Jun-09-21
Initiated Piper Sandler: Overweight Dec-23-20
Initiated Ladenburg Thalmann: Buy Oct-14-20
More Upgrades & Downgrades

Similar to COGT

biotechnology BGNE
$130.05
price down icon 1.63%
biotechnology BMRN
$90.00
price down icon 0.56%
biotechnology ALNY
$144.72
price up icon 0.37%
biotechnology GMAB
$28.33
price down icon 0.70%
biotechnology BNTX
$85.70
price down icon 0.75%
biotechnology ARGX
$360.62
price down icon 1.31%
Open in Yahoo | Open in Google | Open in Finviz
Cap:     |  Volume (24h):